Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement

Author:

Ahluwalia Rupa1ORCID,Baldeweg Stephanie E.234,Boelaert Kristien5,Chatterjee Krishna6ORCID,Dayan Colin7,Okosieme Onyebuchi7ORCID,Priestley Julia8,Taylor Peter7ORCID,Vaidya Bijay9ORCID,Zammitt Nicola10,Pearce Simon H.11ORCID

Affiliation:

1. Department of Diabetes & Endocrinology Norfolk and Norwich University Hospitals NHS Trust Norwich UK

2. Department of Diabetes & Endocrinology University College London London UK

3. Centre for Obesity & Metabolism, Department of Experimental & Translational Medicine, Division of Medicine University College London Hospitals London UK

4. The RCP Joint Specialties Committee and The Clinical Committee Society for Endocrinology Bristol UK

5. Institute for Applied Health Research, College of Medical and Dental Sciences University of Birmingham Birmingham UK

6. Wellcome‐MRC Institute of Metabolic Sciences University of Cambridge Cambridge UK

7. Thyroid Research Group, Heath Park Cardiff University Cardiff UK

8. British Thyroid Foundation Harrogate UK

9. Department of Endocrinology Royal Devon University Hospital |University of Exeter Medical School Exeter UK

10. Edinburgh Centre for Endocrinology and Diabetes Royal Infirmary of Edinburgh Edinburgh UK

11. BioMedicine West, Translational and Clinical Research Institute Newcastle University Newcastle upon Tyne UK

Abstract

AbstractPersistent symptoms in patients treated for hypothyroidism are common. Despite more than 20 years of debate, the use of liothyronine for this indication remains controversial, as numerous randomised trials have failed to show a benefit of treatment regimens that combine liothyronine (T3) with levothyroxine over levothyroxine monotherapy. This consensus statement attempts to provide practical guidance to clinicians faced with patients who have persistent symptoms during thyroid hormone replacement therapy. It applies to non‐pregnant adults and is focussed on care delivered within the UK National Health Service, although it may be relevant in other healthcare environments.The statement emphasises several key clinical practice points for patients dissatisfied with treatment for hypothyroidism. Firstly, it is important to establish a diagnosis of overt hypothyroidism; patients with persistent symptoms during thyroid hormone replacement but with no clear biochemical evidence of overt hypothyroidism should first have a trial without thyroid hormone replacement. In those with established overt hypothyroidism, levothyroxine doses should be optimised aiming for a TSH in the 0.3–2.0 mU/L range for 3 to 6 months before a therapeutic response can be assessed. In some patients, it may be acceptable to have serum TSH below reference range (e.g. 0.1–0.3 mU/L), but not fully suppressed in the long term.We suggest that for some patients with confirmed overt hypothyroidism and persistent symptoms who have had adequate treatment with levothyroxine and in whom other comorbidities have been excluded, a trial of liothyronine/levothyroxine combined therapy may be warranted. The decision to start treatment with liothyronine should be a shared decision between patient and clinician. However, individual clinicians should not feel obliged to start liothyronine or to continue liothyronine medication provided by other health care practitioners or accessed without medical advice, if they judge this not to be in the patient's best interest.

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3